BiotechTube

bevacizumab

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Age-related Macular Degeneration

Conditions

Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema

Trial Timeline

Oct 1, 2020 → Feb 10, 2021

NCT ID
NCT04516278

About bevacizumab

bevacizumab is a phase 3 stage product being developed by Outlook Therapeutics for Age-related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT04516278. Target conditions include Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration.

What happened to similar drugs?

11 of 20 similar drugs in Age-related Macular Degeneration were approved

Approved (11) Terminated (4) Active (6)
✅FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
✅FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
❌E10030 + ranibizumab + E10030 sham intravitreal injectionAstellas PharmaPhase 3
❌E10030 + bevacizumab or aflibercept + E10030 sham injectionAstellas PharmaPhase 3
❌E10030 + ranibizumab + E10030 sham intravitreal injectionAstellas PharmaPhase 3
🔄Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab ControlAbbViePhase 3
✅ranibizumabNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05112861Phase 3Active
NCT04516278Phase 3Completed

Competing Products

20 competing products in Age-related Macular Degeneration

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
33
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
33
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Fovista® + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
27
MA09-hRPEAstellas PharmaPre-clinical
26
volociximabAstellas PharmaPhase 1
29
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
27
Avacincaptad PegolAstellas PharmaPhase 1
29
E10030 + ranibizumab + E10030 sham intravitreal injectionAstellas PharmaPhase 3
32
E10030Astellas PharmaPhase 1
29
ASP7317 + tacrolimus + trimethoprim-sulfamethoxazole + Acyclovir + NystatinAstellas PharmaPhase 1
36
Sub-retinal transplantation of MA09-hRPE cells + tacrolimus and mycophenolate mofetil + Placebo tacrolimus and mycophenolate mofetilAstellas PharmaPhase 2
27
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
35
E10030 + bevacizumab or aflibercept + E10030 sham injectionAstellas PharmaPhase 3
32
Fovista® (anti-PDGF BB) plus anti-VEGFAstellas PharmaPhase 2
27